We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AzurRx BioPharma Inc | NASDAQ:AZRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.45 | 3.41 | 3.51 | 0 | 01:00:00 |
Delaware
|
001-37853
|
46-4993860
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
777 Yamato Road, Suite 502
Boca Raton, Florida
|
|
33431
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
AZRX
|
Nasdaq
Capital Market
|
Exhibit No.
|
|
Description
|
|
|
|
|
Amended
and Restated Underwriting Agreement, dated July 22, 2021, between
AzurRx BioPharma, Inc. and H.C. Wainwright & Co.,
LLC
|
|
|
|
|
|
Form of
Wainwright Warrant
|
|
|
|
|
|
Opinion
of Lowenstein Sandler LLP
|
|
|
|
|
|
Consent
of Lowenstein Sandler LLP (included in Exhibit 5.1)
|
|
|
|
|
|
Press
Release dated July 22, 2021 (announcing pricing of
offering)
|
|
|
|
|
|
Press
Release dated July 22, 2021 (announcing upsizing of
offering)
|
|
|
|
|
99.3
|
|
Press Release
dated July 27, 2021 (announcing closing of
offering)
|
|
AzurRx BioPharma, Inc.
|
|
||
|
|
|
|
|
Date:
July 27, 2021
|
By:
|
/s/
Daniel Schneiderman
|
|
|
|
|
Name: Daniel Schneiderman
|
|
|
|
|
Title: Chief Financial Officer
|
|
|
1 Year AzurRx BioPharma Chart |
1 Month AzurRx BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions